Showing 3551-3560 of 5693 results for "".
- BlueRock Therapeutics Announces First Patient Treated in Phase 1/2a Trial of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-announces-first-patient-treated-in-phase-12a-trial-of-opct-001-for-primary-photoreceptor-diseases/2482877/Bayer and BlueRock Therapeutics announced that the first patient received the investigational therapy in CLARICO, a phase 1/2a clinical trial of OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. OpCT-00
- Beacon Therapeutics Completes Enrollment in Registrational Phase 2/3 VISTA Trial of laru-zova for Patients with XLRPhttps://modernod.com/news/beacon-therapeutics-completes-enrollment-in-registrational-phase-23-vista-trial-of-laru-zova-for-patients-with-xlrp-1/2482875/Beacon Therapeutics announced it has completed enrollment in its registrational phase 2/3 VISTA trial evaluating laru-zova for the treatment of X-linked retinitis pigmentosa (XLRP). The study enrolled eligible male patients aged 12 to 50 across sites in North America, the United Kingdom
- First Patient Dosed in the Phase 1 Trial of PulseSight Therapeutics’ Investigational PST-611 Treatment for Dry AMD/GAhttps://modernod.com/news/first-patient-dosed-in-the-phase-1-trial-of-pulsesight-therapeutics-investigational-pst-611-treatment-for-dry-amdga/2482874/PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial (PST-611-CT1) assessing the safety and tolerability of its lead program, PST-611, in humans. PST-611 is a first-in-class non-viral vectorized
- Bausch + Lomb Launches Dry Eye Education Campaignhttps://modernod.com/news/bausch-lomb-launches-dry-eye-education-campaign/2482872/Bausch + Lomb announced the launch of “Eyes Tell the Story: The Impact of Dry Eye,” a new awareness campaign designed to spotlight the burden of dry eye symptoms through storytelling, photography, and insights from the company’s latest nationw
- Feliqs Secures $9 Million Series A to Advance FLQ-101 Clinical Trial for Retinopathy of Prematurityhttps://modernod.com/news/feliqs-secures-9-million-series-a-to-advance-flq-101-clinical-trial-for-retinopathy-of-prematurity/2482869/Feliqs Corp. announced the successful completion of a $9 million Series A financing round to advance the company's lead investigational therapy, FLQ-101, into clinical development. Designed as a once-daily oral or intravenous formulation, FLQ-101 aims
- Glaukos Receives EU MDR Certification for iStent infinite and iStent inject Whttps://modernod.com/news/glaukos-announces-european-union-mdr-certification-for-istent-infinite-and-istent-inject-w/2482868/Glaukos received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite, along with several of its other MIGS technologies, including iStent inject W. Glauko
- The European Commission (EC) Approves Eylea 8 mg for Extended Treatment Intervals of Up to 6 Monthshttps://modernod.com/news/the-european-commission-ec-approves-eylea-8-mg-for-extended-treatment-intervals-of-up-to-6-months/2482867/The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8 mg with extended treatment intervals of up to 6 months for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Eylea 8 mg was previously
- Ocumetics Initiates First-In-Human Study of Accommodating Intraocular Lenshttps://modernod.com/news/ocumetics-initiates-first-in-human-study-of-accommodating-intraocular-lens/2482866/Ocumetics Technology has initiated the first-in-human (FIH) clinical studies for its accommodating intraocular lens, known as the Ocumetics Lens. Designed to mimic the natural focusing ability of the youthful hu
- Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet AMDhttps://modernod.com/news/ashvattha-therapeutics-presents-positive-interim-phase-2-results-for-subcutaneous-migaldendranib-treatment-for-dme-and-wet-amd/2482864/Ashvattha Therapeutics announced interim results from its ongoing phase 2 study of subcutaneous (subQ) migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The data were presented at the MaculArt Meeting, June 29–July 1, 2025
- ForSight Robotics Secures $125 Million in Series B Fundinghttps://modernod.com/news/forsight-robotics-secures-125-million-in-series-b-funding-addressing-global-surgeon-shortage-and-demand-for-ophthalmic-surgery/2482862/ForSight Robotics announced it has completed a $125M Series B round, led by Eclipse. The investment accelerates the next growth phase for the ORYOM Platform, the world’s first robotic surgery platform for cataract and other eye diseases designed to enhance surgical precision, incr